GALLIC ACID IMPROVES OXIDATIVE STRESS AND INFLAMMATION THROUGH REGULATING MICRORNAS EXPRESSIONS IN THE BLOOD OF...

Area of Science:

• Cardiovascular Science
• Endocrinology
• Biochemistry

Background:

• Diabetes mellitus is linked to endothelial dysfunction and diabetic cardiomyopathy.
• Gallic acid (GA) shows potential in managing diabetes-related cardiovascular complications.
• Plasma miR-24 and miR-126 are implicated in endothelial dysfunction associated with diabetes.

Purpose of the Study:

• To investigate the therapeutic effects of Gallic acid (GA) on plasma miR-24 and miR-126 levels in a rat model of diabetes.
• To assess GA's impact on cardiovascular risk factors in diabetic rats.

Main Methods:

• Adult male Sprague-Dawley rats were allocated into control, diabetic, and diabetic groups treated with GA (25 mg/kg/day via gavage) for eight weeks.
• Key parameters measured included blood glucose, body weight, lipid profile, blood pressure, plasma miR-24 and miR-126, and oxidative/inflammatory biomarkers.

Main Results:

• Diabetic rats exhibited elevated blood glucose, lipids (TC, TG, VLDL-c, LDL-c), MDA, IL-6, TNF-α, and blood pressure, alongside reduced body weight, HDL-c, and TAC.
• Gallic acid (GA) treatment reversed these adverse effects, restoring normal levels of body weight, blood pressure, lipids, glucose, HDL-c, MDA, TAC, IL-6, TNF-α, miR-24, and miR-126 compared to diabetic rats.

Conclusions:

• Gallic acid (GA) demonstrates protective effects against diabetes-induced inflammation, oxidative stress, and hypotension.
• These beneficial actions of GA are likely mediated through the upregulation of plasma miR-24 and miR-126 levels.